- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04839237
The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:The rapid growth of obese or overweight people in the world has become a major social problem. Obese often associated with kinds of metabolic disorders, especially type 2 diabetes, and Liraglutide can effectively reduce weight and improve blood glucose.Previous studies have indicated that most patients will experience different degrees of weight loss after using Liraglutide, but there is also a small number of patients with no significant weight loss.The gene polymorphism among individuals may affect the weight loss effect of Liraglutide.
Objectives:1.To find the relationships between genetic variants and the response of Liraglutide to treatment of obese patients.2.To investigate the effects of Liraglutide on weight, metabolism (blood glucose, blood lipid, uric acid, etc.) and gut microbiota in obese Chinese patients.
Intervention:Half of participants will receive Liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive Liraglutide and metformin in combination.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 to 65 years (to the date of screening);
- The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm).
- Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial.
- Weight stable for more than 3 months (weight fluctuations <5%).
Exclusion Criteria:
- Pregnant female.
- Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others.
- Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis.
- Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes.
- Nearly a month had surgery, trauma, infection and so on.
- Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators.
- Poor medication compliance or serious side effects (severe rash, syncope, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liraglutide
Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
|
The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg
per day, subcutaneous injection.
Other Names:
|
Experimental: Liraglutide combined with metformin
Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
|
The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg
per day, subcutaneous injection.For metformin,during three months:0.5g
each time, 3 times per day,oral.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight Change at 3 months
Time Frame: baseline and 3 months
|
Measured in kilograms
|
baseline and 3 months
|
Genotype
Time Frame: baseline
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut microbiota composition
Time Frame: 3 months
|
Gut microbiota composition is assessed by 16S rRNA pyrosequencing.
This analysis allows to obtain the relative abundance (%) of the different bacterial taxa and OTUs (operational taxonomic units).
|
3 months
|
Change in waist circumference
Time Frame: baseline and 3 months
|
Measured in cm
|
baseline and 3 months
|
Change in systolic blood pressure
Time Frame: baseline and 3 months
|
Measured in mmHg
|
baseline and 3 months
|
Change in diastolic blood pressure
Time Frame: baseline and 3 months
|
Measured in mmHg
|
baseline and 3 months
|
Change in HbA1c
Time Frame: baseline and 3 months
|
Measured in %
|
baseline and 3 months
|
Change in plasma glucose
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Change in insulin
Time Frame: baseline and 3 months
|
Measured in μU/ml
|
baseline and 3 months
|
Change in lipids-total cholesterol
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Change in lipids-low density lipoprotein cholesterol
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Change in lipids-high density lipoprotein cholesterol
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Change in lipids-triglycerides
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Change in lipids-free fatty acids
Time Frame: baseline and 3 months
|
Measured in μmol/l
|
baseline and 3 months
|
Change in Uric Acid
Time Frame: baseline and 3 months
|
Measured in mmol/l
|
baseline and 3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201710832
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Liraglutide
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Novo Nordisk A/SCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Merck Sharp & Dohme LLCCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Parker Research InstituteCompletedOsteoarthritis, KneeDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark